中国医药：拟5.25亿元购买则正医药70%股权

Core Viewpoint - The company has signed a share purchase agreement to acquire 70% of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a cash investment of 525 million RMB, aiming to enhance its capabilities in pharmaceutical R&D innovation and address current shortcomings in its R&D system [1] Group 1: Transaction Details - The total cash investment for the acquisition is 525 million RMB [1] - The transaction involves 13 counterparties who collectively hold the shares being purchased [1] - The acquisition will result in Shanghai Zezheng becoming a wholly-owned subsidiary of the company [1] Group 2: Strategic Objectives - The primary goal of the transaction is to strengthen the company's overall strength in the pharmaceutical R&D innovation sector [1] - The acquisition is intended to bridge the gap in the current R&D system and facilitate a full industry chain from research and development to production [1] - The transaction has been approved by the board of directors and does not require shareholder approval [1]